Clinical Trial Update: Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sildenafil as an added effect in individuals with dapoxetine non-responding mono-symptomatic premature ejaculation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• Dapoxetine (dapoxetine)
• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Al-Azhar University | Conditions: Premature Ejaculation | Phase 2 | Status: UNKNOWN